EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk - Takeaways - MDSpire

EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk

  • By

  • Suman Atluri

  • Radha Rao

  • March 9, 2026

  • 0 min

Share

  • 1

    Pitavastatin significantly reduced major adverse cardiovascular events by 35% in HIV-positive individuals with moderate to low risk factors.

  • 2

    The REPRIEVE trial involved participants aged 40-75 years on stable antiretroviral therapy without clinical ASCVD.

  • 3

    Despite a median 10-year ASCVD risk of 4.5%, the placebo group experienced a higher observed MACE rate of 7.3%.

  • 4

    Muscle-related symptoms and incident diabetes were more frequent in the pitavastatin group compared to placebo.

  • 5

    Guidelines now recommend statin therapy for HIV-positive individuals aged 40-75, regardless of lipid levels or ASCVD risk.

Original Source(s)

EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk

  • by Suman Atluri, Radha Rao

  • March 9, 2026

Related Content

Thirty-Year Changes in Stroke Demographics in the Saudi National Guard Community (1982–1992 and 2013–2024)

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.